Axel Vater

This inventor holds 12 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignees: Noxxon Pharma Ag, Aptarion Biotech Ag, Bayer Schering Pharma Ag. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Axel Vater. Retrieved from https://idiyas.com/inventor/axel-vater

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 8)

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 36(Granted Patents)

Company Filing History:

Bayer Schering Pharma Ag

patents

Years Active: 2011-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12359206 - CXCL8 binding nucleic acids (2025-07-15),

2. 12188021 - C5a binding nucleic acids (2025-01-07),

3. 11492625 - C5a binding nucleic acids (2022-11-08),

4. 11371045 - Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors (2022-06-28),

5. 10590424 - C5a binding nucleic acids (2020-03-17),

6. 9976145 - Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same (2018-05-22),

7. 9518265 - C5a binding nucleic acids (2016-12-13),

8. 9074214 - Use of spiegelmers (2015-07-07),

9. 8497250 - Use of spiegelmers to inhibit an intracellular target molecule (2013-07-30),

10. 8383789 - Vasopressin-binding L-nucleic acid (2013-02-26),

11. 7879991 - CGRP binding nucleic acids (2011-02-01),

12. 7879314 - Optical imaging of rheumatoid arthritis (2011-02-01),

Title: The Innovations of Axel Vater

Introduction

Axel Vater is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of nucleic acid molecules. With a total of 12 patents to his name, Vater's work has the potential to impact various medical applications.

Latest Patents

Among his latest patents, Vater has developed a CXCL8 binding nucleic acid molecule. This invention relates to an L-nucleic acid molecule capable of binding to human CXCL8, featuring a specific nucleotide sequence. Another notable patent is for C5a binding nucleic acids, which involves a nucleic acid molecule that can bind to human C5a, also characterized by a unique nucleotide sequence. These innovations showcase his expertise in molecular biology and therapeutic development.

Career Highlights

Throughout his career, Axel Vater has worked with notable companies such as Noxxon Pharma AG and Aptarion Biotech AG. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the biotechnology sector.

Collaborations

Vater has collaborated with esteemed colleagues, including Christian Maasch and Sven Klussmann. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Axel Vater's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in medical science and therapeutic solutions.

Profile summary based on public USPTO records.